Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer.

Li, Zheqi; Spoelstra, Nicole S; Sikora, Matthew J; Sams, Sharon B; Elias, Anthony; Richer, Jennifer K; Lee, Adrian V; Oesterreich, Steffi

Li, Zheqi; Spoelstra, Nicole S; Sikora, Matthew J; Sams, Sharon B; Elias, Anthony; Richer, Jennifer K; Lee, Adrian V; Oesterreich, Steffi.

Afiliación

Li Z; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
Spoelstra NS; Women's Cancer Research Center, Magee Women's Research Institute, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Sikora MJ; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Sams SB; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Elias A; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Richer JK; School of Medicine, Division of Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Lee AV; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Oesterreich S; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.

NPJ Breast Cancer ; 8(1): 62, 2022 May 10.

Article en En | MEDLINE | ID: mdl-35538119

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: NPJ Breast Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google